Limits...
EGFR-targeted delivery of DOX-loaded Fe 3 O 4 @ polydopamine multifunctional nanocomposites for MRI and antitumor chemo-photothermal therapy

View Article: PubMed Central - PubMed

ABSTRACT

Multifunctional nanocomposites that have multiple therapeutic functions together with real-time imaging capabilities have attracted intensive concerns in the diagnosis and treatment of cancer. This study developed epidermal growth factor receptor (EGFR) antibody-directed polydopamine-coated Fe3O4 nanoparticles (Fe3O4@PDA NPs) for magnetic resonance imaging and antitumor chemo-photothermal therapy. The synthesized Fe3O4@PDA-PEG-EGFR-DOX NPs revealed high storage capacity for doxorubicin (DOX) and high photothermal conversion efficiency. The cell viability assay of Fe3O4@PDA-PEG-EGFR NPs indicated that Fe3O4@ PDA-PEG-EGFR NPs had no cell cytotoxicity. However, Fe3O4@PDA-PEG-EGFR-DOX NPs could significantly decrease cell viability (~5% of remaining cell viability) because of both photothermal ablation and near-infrared light-triggered DOX release. Meanwhile, the EGFR-targeted Fe3O4@PDA-PEG-EGFR-DOX NPs significantly inhibited the growth of tumors, showing a prominent in vivo synergistic antitumor effect. This study demonstrated the potential of using Fe3O4@PDA NPs for combined cancer chemo-photothermal therapy with increased efficacy.

No MeSH data available.


Magnetic properties of Fe3O4@PDA-PEG-EGFR NPs.Notes: (A) Photographs of Fe3O4@PDA-PEG-EGFR in water with and without a magnet. (B) Magnetization loops of Fe3O4@PDA-PEG-EGFR NPs. (C) T2-weighted MR images of Fe3O4@PDA-PEG-EGFR solutions at different concentrations. (D) T2 relaxation rates (R2) of Fe3O4@PDA-PEG-EGFR solutions at different concentrations.Abbreviations: MR, magnetic resonance; PDA, polydopamine; PEG, polyethylene glycol; NP, nanoparticle.
© Copyright Policy
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC5391832&req=5

f3-ijn-12-2899: Magnetic properties of Fe3O4@PDA-PEG-EGFR NPs.Notes: (A) Photographs of Fe3O4@PDA-PEG-EGFR in water with and without a magnet. (B) Magnetization loops of Fe3O4@PDA-PEG-EGFR NPs. (C) T2-weighted MR images of Fe3O4@PDA-PEG-EGFR solutions at different concentrations. (D) T2 relaxation rates (R2) of Fe3O4@PDA-PEG-EGFR solutions at different concentrations.Abbreviations: MR, magnetic resonance; PDA, polydopamine; PEG, polyethylene glycol; NP, nanoparticle.

Mentions: Because of the presence of magnetic iron oxide core, the Fe3O4@PDA-PEG-EGFR NPs displayed strong magnetic property. When placed beside a magnet, the Fe3O4@PDA-PEG-EGFR NPs in aqueous solution was attracted by a magnet, which was almost unchanged without a magnet (Figure 3A). The strong super paramagnetism of Fe3O4@PDA-PEG-EGFR NPs was further revealed by the field-dependent magnetization hysteresis loop (Figure 3B). Fe3O4 NPs have been widely used as a T2-contrast agent for MRI.24,25 As shown in Figure 3C and D, the T2-weighted MR images exhibited increasingly darkening effect with the increase of Fe3O4@PDA-PEG-EGFR NPs concentration. This result suggested that Fe3O4@PDA-PEG-EGFR NPs could be used as a T2-weighted MRI contrast agent.


EGFR-targeted delivery of DOX-loaded Fe 3 O 4 @ polydopamine multifunctional nanocomposites for MRI and antitumor chemo-photothermal therapy
Magnetic properties of Fe3O4@PDA-PEG-EGFR NPs.Notes: (A) Photographs of Fe3O4@PDA-PEG-EGFR in water with and without a magnet. (B) Magnetization loops of Fe3O4@PDA-PEG-EGFR NPs. (C) T2-weighted MR images of Fe3O4@PDA-PEG-EGFR solutions at different concentrations. (D) T2 relaxation rates (R2) of Fe3O4@PDA-PEG-EGFR solutions at different concentrations.Abbreviations: MR, magnetic resonance; PDA, polydopamine; PEG, polyethylene glycol; NP, nanoparticle.
© Copyright Policy
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC5391832&req=5

f3-ijn-12-2899: Magnetic properties of Fe3O4@PDA-PEG-EGFR NPs.Notes: (A) Photographs of Fe3O4@PDA-PEG-EGFR in water with and without a magnet. (B) Magnetization loops of Fe3O4@PDA-PEG-EGFR NPs. (C) T2-weighted MR images of Fe3O4@PDA-PEG-EGFR solutions at different concentrations. (D) T2 relaxation rates (R2) of Fe3O4@PDA-PEG-EGFR solutions at different concentrations.Abbreviations: MR, magnetic resonance; PDA, polydopamine; PEG, polyethylene glycol; NP, nanoparticle.
Mentions: Because of the presence of magnetic iron oxide core, the Fe3O4@PDA-PEG-EGFR NPs displayed strong magnetic property. When placed beside a magnet, the Fe3O4@PDA-PEG-EGFR NPs in aqueous solution was attracted by a magnet, which was almost unchanged without a magnet (Figure 3A). The strong super paramagnetism of Fe3O4@PDA-PEG-EGFR NPs was further revealed by the field-dependent magnetization hysteresis loop (Figure 3B). Fe3O4 NPs have been widely used as a T2-contrast agent for MRI.24,25 As shown in Figure 3C and D, the T2-weighted MR images exhibited increasingly darkening effect with the increase of Fe3O4@PDA-PEG-EGFR NPs concentration. This result suggested that Fe3O4@PDA-PEG-EGFR NPs could be used as a T2-weighted MRI contrast agent.

View Article: PubMed Central - PubMed

ABSTRACT

Multifunctional nanocomposites that have multiple therapeutic functions together with real-time imaging capabilities have attracted intensive concerns in the diagnosis and treatment of cancer. This study developed epidermal growth factor receptor (EGFR) antibody-directed polydopamine-coated Fe3O4 nanoparticles (Fe3O4@PDA NPs) for magnetic resonance imaging and antitumor chemo-photothermal therapy. The synthesized Fe3O4@PDA-PEG-EGFR-DOX NPs revealed high storage capacity for doxorubicin (DOX) and high photothermal conversion efficiency. The cell viability assay of Fe3O4@PDA-PEG-EGFR NPs indicated that Fe3O4@ PDA-PEG-EGFR NPs had no cell cytotoxicity. However, Fe3O4@PDA-PEG-EGFR-DOX NPs could significantly decrease cell viability (~5% of remaining cell viability) because of both photothermal ablation and near-infrared light-triggered DOX release. Meanwhile, the EGFR-targeted Fe3O4@PDA-PEG-EGFR-DOX NPs significantly inhibited the growth of tumors, showing a prominent in vivo synergistic antitumor effect. This study demonstrated the potential of using Fe3O4@PDA NPs for combined cancer chemo-photothermal therapy with increased efficacy.

No MeSH data available.